Get started
Author

Antonella De Luca

Observed names: A De Luca, A. De Luca, A. De luca, A. Luca, A. de Luca, Antonella DeLuca, Antonella de Luca, De Luca, De Luca, Antonella
ORCID: 0000-0001-5762-447X
Observed ORCID: 0000-0001-5762-447X
OpenAlex ID: A5013429068
Epidermal growth factor receptor (EGFR) signaling in cancer
2005 · Nicola Normanno, Antonella De Luca, et al. · Gene · 2,042
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
2012 · Antonella De Luca, Monica R Maiello, et al. · Expert Opinion on Therapeutic Targets · 735
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
2009 · Nicola Normanno, Sabine Tejpar, et al. · Nature Reviews Clinical Oncology · 436
The role of the EGFR signaling in tumor microenvironment
2007 · Antonella De Luca, Adele Carotenuto, et al. · Journal of Cellular Physiology · 359
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003 · N Normanno, C Bianco, et al. · Endocrine Related Cancer · 336
PDF
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005 · Nicola Normanno, Massimo Di Maio, et al. · Endocrine Related Cancer · 286
PDF
The ErbB Receptors and their Ligands in Cancer: An Overview
2005 · N. Normanno, C. Bianco, et al. · Current Drug Targets · 275
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
2002 · N. Normanno, M. Campiglio, et al. · Annals of Oncology · 273
VEGF as a potential target in lung cancer
2017 · Daniela Frezzetti, Marianna Gallo, et al. · Expert Opinion on Therapeutic Targets · 235
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo
2003 · Heather B. Adkins, Caterina Bianco, et al. · Journal of Clinical Investigation · 158
PDF
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios
2018 · Nicola Normanno, Andres Cervantes, et al. · Cancer Treatment Reviews · 148
Cripto-1 Activates Nodal- and ALK4-Dependent and -Independent Signaling Pathways in Mammary Epithelial Cells
2002 · Caterina Bianco, Heather B. Adkins, et al. · Molecular and Cellular Biology · 147
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
2006 · Nicola Normanno, Antonella De Luca, et al. · Journal of Cellular Physiology · 144
PDF
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action?
2002 · Nicola Normanno, Monica R. Maiello, et al. · Journal of Cellular Physiology · 140
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
2020 · Antonella De Luca, Riziero Esposito Abate, et al. · International Journal of Molecular Sciences · 131
PDF
Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells
2010 · Antonella De Luca, Marianna Gallo, et al. · Journal of Cellular Physiology · 113
Mesenchymal stem cell‐derived interleukin‐6 and vascular endothelial growth factor promote breast cancer cell migration
2012 · Antonella De Luca, Luana Lamura, et al. · Journal of Cellular Biochemistry · 102
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis
2005 · N Normanno, A De Luca, et al. · Endocrine Related Cancer · 98
PDF
EGFR mutations in lung cancer: from tissue testing to liquid biopsy
2015 · Francesca Fenizia, Antonella De Luca, et al. · Future Oncology · 94
Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
2016 · Anna Maria Rachiglio, Riziero Esposito Abate, et al. · Oncotarget · 90
PDF
Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer
2006 · Caterina Bianco, Luigi Strizzi, et al. · Clinical Cancer Research · 83
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer
2011 · M. Gallo, A. De Luca, et al. · Annals of Oncology · 80
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
2019 · Anna Rachiglio, Francesca Fenizia, et al. · Cancers · 74
PDF
Target-based therapies in breast cancer: current status and future perspectives
2009 · Nicola Normanno, Alessandro Morabito, et al. · Endocrine Related Cancer · 73
PDF
Prognostic value of circulating tumor cells’ reduction in patients with extensive small-cell lung cancer
2014 · Nicola Normanno, Antonio Rossi, et al. · Lung Cancer · 69
Works count: 157
Citation count: 8,667
H-index: 42
I10-index: 81
Year
Topic
Type